Dyve Bioscience touts proof-of-concept study for transdermal painkiller

Dyve Bioscience this week touted data from a human proof-of-concept pilot study of its transdermal sodium bicarbonate therapy for pain reduction in people with acute gout flare.

The study enrolled 24 people with a history of gout. Those in the active treatment group were given lotion containing sodium bicarbonate and menthol, while those in the placebo group were given lotion without sodium bicarbonate or menthol. Investigators told the participants to report to the clinic within 36 hours of flare onset.

Study participants applied 10 mL of lotion every four hours, three times per day to the entire limb of the target join as identified by the investigator. Follow-up time points included 15 and 30 minutes, 1, 2, 4, 6, 8, 10, 12 and 14 days – data were collected by phone.

While the company did not include the study’s full results in a statement, Dyve Bioscience reported that the study demonstrated the efficacy of topical sodium bicarbonate for the treatment of pain associated with an acute gout flare.

“Our mission is to change the standard of care for people suffering from acute gout pain, by providing immediate relief through a safe transdermal technology,” Lisa Misell, VP of clinical and medical affairs, said in prepared remarks. “We are pleased with the results of this study and the company is preparing to advance the treatment into the next phase of development.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.